NCT03250624

Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to its vehicle.

Detailed description

Study application was performed once daily, 7 days a week for 6 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	CD5024 0.3% cream	Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
DRUG	Placebo	Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-06-26
• Completion: 2017-06-26
• First posted: 2017-08-15
• Last updated: 2023-05-01
• Results posted: 2023-05-01

Locations

5 sites across 1 country: Canada